Long-acting injectable HIV prevention and opioid treatment for people in jail and after release
NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings
This project will compare monthly injectable HIV prevention plus long-acting buprenorphine against daily pills to help adults with opioid use disorder who are incarcerated or recently released.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11361486 on NIH RePORTER |
What this research studies
You would be offered a co-packaged option of long-acting injectable PrEP and long-acting injectable buprenorphine while in jail or prison and continued after release. The team will work with correctional and community clinics in Maryland and Washington, DC to set up and support delivery of the injectables. Some participants will receive the injectable combination while others receive the usual oral PrEP and sublingual buprenorphine to compare outcomes. Study staff will follow people during incarceration and after release to track uptake, continuity of care, HIV prevention, and opioid-related outcomes.
Who could benefit from this research
Good fit: Adults (21+) who are in correctional settings or recently released, have opioid use disorder, and are at risk for HIV are the best fit for this project.
Not a fit: People without opioid use disorder, at very low risk for HIV, or who do not want injectable medications are unlikely to benefit.
Why it matters
Potential benefit: If successful, this approach could improve continuity of HIV prevention and opioid treatment, lowering HIV infections and relapse after release.
How similar studies have performed: Long-acting PrEP and injectable buprenorphine have shown promise separately, but combining and delivering them in correctional and post-release settings is a newer approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Brinkley-Rubinstein, Lauren — Duke University
- Study coordinator: Brinkley-Rubinstein, Lauren
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.